None listed
Conditions
Interventions
Drug : After the administration of Oseltamivir 75 mg capsule, three tablets of Dexamethasone 0.5 mg tablet were administered repeatedly for six days
Sponsors
Bundang CHA General Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Subjects who listened to the description about characteristics of this clinical trial and signed the IRB approved consent form before the whole screening tests 2) Healthy Korean male volunteers who are 20 to 45 years old
Exclusion criteria
Exclusion criteria: 1) Subject who have clinical evidence of significant respiratory, cardiological, nephrological, gastrointestinal, endocrinological, hematological, neurological (included ataxia), psychiatric disorders or other chronic disorders, alcohol or substance addiction 2) Subjects who take medicine which is known to have significant drug interaction or is judged as inappropriate by researcher within 14 days of administration of drugs for clinical trial 3) Subjects who donated blood within 30 days from the start of clinical trial or who participated in the clinical trial of other drugs for clinical trials or post marketing surveillance. 4) Subjects who have experienced significant adverse reactions such as hypersensitivity to drugs for clinical trials 5) Subjects who planned pregnancy or cannot use established contraceptions (e.g. infertility operation of the subject or partner, intrauterine contraceptive device of the partner, barrier contraception, diaphragm or condom use in combination during the test 6) Female subject who were pregnant or breast-feeding 7) Subject who are judged as inappropriate for participating in the clinical trial by researcher because of causes including the test result of clinical laboratory
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax, AUClast, AUCinf, CL/F, CLR/F, t1/2, metabolic ratio | — |
Countries
Korea, Republic of
Contacts
Public ContactMin-Kyoung Kim
Bundang CHA General Hospital
Outcome results
None listed